Metabolic pathways are fundamental to cellular function, providing the energy and building blocks necessary for growth, maintenance, and response to environmental changes. Dysregulation of metabolic enzymes and pathways is linked to a variety of diseases, including cancer, metabolic disorders, and neurodegenerative diseases. Targeting these pathways through drug discovery allows for the development of therapies that can correct metabolic imbalances or exploit metabolic vulnerabilities in diseased cells.
ADP-Glo Assay: In this assay, kinases interact with their substrates in the presence of ATP, which donates a phosphate group and produces ADP as a byproduct. After a set reaction time, an ADP-Glo reagent is added to stop the reaction and deplete remaining ATP, ensuring that only newly generated ADP is measured. A detection reagent then converts ADP back to ATP, which reacts with luciferase to produce a chemiluminescent signal proportional to kinase activity.
Fluorescence Intensity (FI) Assay for NADP(H): This assay uses NADH/NADPH as a hydrogen carrier in the presence of a dehydrogenase enzyme, where it cycles between reduced (NADH/NADPH) and oxidized (NAD/NADP) forms. Upon excitation at 340 nm, NADH/NADPH emits fluorescence at 460 nm, while oxidized NAD/NADP forms do not emit. Fluorescence intensity directly reflects the concentration of NADH/NADPH, indicating the enzymatic activity.
Absorbance (Abs) Assay: In this method, the substrate undergoes hydrolysis by the enzyme, producing a detectable product with a specific absorption peak. The optical density (OD) value of this product is measured using a spectrophotometer, providing a quantitative measure of enzyme activity based on absorbance changes.
Target | Synonyms | Category | Reference Compound | Assay Format |
---|---|---|---|---|
PFKFB3 | IPFK2; PFK2 | Kinase | AZ PFKFB3 26 | ADP-Glo |
15-PGDH | HPGD; PGDH1 | Dehydrogenase | ML148 | FI |
LDHA | LDH1; LDHM | Dehydrogenase | LDH-IN-1 | FI |
LDHB | LDH-H | Dehydrogenase | LDH-IN-1 | FI |
IDH1 | PICD | Dehydrogenase | (R,R)-GSK321 | FI |
IDH2 | ICD-M | Dehydrogenase | AGI-6780 | FI |
IDH1[R132H] | / | Mutant Dehydrogenase | Ivosidenib | FI |
IDH2[R132C] | / | Mutant Dehydrogenase | AGI-6780 | FI |
IDH1[R100A] | / | Mutant Dehydrogenase | Ivosidenib | FI |
IDH1[R100Q] | / | Mutant Dehydrogenase | Ivosidenib | FI |
IDH1[G97D] | / | Mutant Dehydrogenase | Ivosidenib | FI |
IDH1[Y139D] | / | Mutant Dehydrogenase | Ivosidenib | FI |
AKR1C1 | DDH, DDH1 | Aldo-keto Reductase | AKR1C1-IN-1 | FI |
AKR1C3 | PGFS | Aldo-keto Reductase | ASP-9521 | FI |
ALDH1A1 | ALDC, ALDH1 | Aldehyde Dehydrogenase | KS100 | FI |
ALDH1A2 | RALDH2 | Aldehyde Dehydrogenase | KS100 | FI |
ALDH2 | ALDM | Aldehyde Dehydrogenase | CVT-10216 | FI |
ALDH3A1 | ALDH3 | Aldehyde Dehydrogenase | KS100 | FI |
IMPDH1 | IMPD1 | Inosine Monophosphate Dehydrogenase | AVN-944 | FI |
IMPDH2 | IMPD2 | Inosine Monophosphate Dehydrogenase | AVN-944 | FI |
MTAP | MSAP | Methylthioadenosine Phosphorylase | MT-DADMe-ImmA | FI |
DHODH | DHOdehase | Dehydrogenase | Brequinar | Abs |
MGLL | MAGL | Hydrolase | JZL195 | Abs |
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.